FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

研究用のみ。 完全な免責事項 →

研究/New Clinical Trial Compares Bariatric Surgery to Semaglutide and Tirzepatide
研究ライブラリに戻る

New Clinical Trial Compares Bariatric Surgery to Semaglutide and Tirzepatide

May 25, 2026
Share
発展中の研究

これらは有望ですが、さらなる検証が必要な発展途上の見解に基づいています。

この分析について

この記事は、最近のニュースアイテムや臨床試験リストのAI補助要約です。ペプチド研究コミュニティにとって迅速でアクセスしやすい概要を提供することを目的としています。正確性のために常に下記リンク先の元のソースをご確認ください。

New Clinical Trial Compares Bariatric Surgery to Semaglutide and Tirzepatide

A recent study published on ClinicalTrials.gov aims to shed light on how the latest anti-obesity medications stack up against traditional surgical treatments. The Phase 4 trial, sponsored by Ali Aminian, is set to compare bariatric surgery with two leading peptide therapies: semaglutide and tirzepatide.

This study comes at a time when the landscape of obesity treatment is rapidly changing due to advancements in peptide therapy. Researchers are eager to understand how these newer medications measure up against surgical interventions that have been the gold standard for severe cases of obesity.

Background

Obesity, a condition affecting millions worldwide, often requires aggressive intervention beyond diet and exercise alone. Traditionally, bariatric surgery has been the go-to option for those with extreme weight issues and related health complications. However, recent years have seen the introduction of powerful peptide-based medications like semaglutide and tirzepatide that promise significant weight loss without the risks associated with surgery.

These medications work by mimicking hormones involved in digestion to increase feelings of fullness and regulate blood sugar levels. They are particularly appealing for patients who might not be surgical candidates due to age, medical history, or personal preference. The goal is to determine if these new treatments can offer comparable benefits to bariatric surgery but with fewer risks.

Key Details

The trial involves a comparison between three interventions: bariatric surgery, semaglutide, and tirzepatide. Researchers are tracking weight loss percentages, changes in body composition, and improvements in obesity-related medical conditions such as type 2 diabetes, hypertension, and cardiovascular disease. The study is currently active but not recruiting participants.

Semaglutide and tirzepatide both belong to the class of drugs known as glucagon-like peptide-1 (GLP-1) receptor agonists, which have been shown in previous studies to induce substantial weight loss over extended periods. These medications are administered through subcutaneous injections once a week or daily, depending on the specific regimen prescribed.

Bariatric surgery, on the other hand, involves altering the digestive system to reduce calorie intake and absorption. Common procedures include gastric bypass and sleeve gastrectomy. While these surgeries yield high weight loss rates, they come with significant risks including infection, blood clots, and nutritional deficiencies.

Key Takeaways

  • Semaglutide and Tirzepatide Show Promising Results: Early studies have demonstrated that these peptide therapies can lead to an average of 15-22% weight reduction over a year.
  • Bariatric Surgery Remains a Gold Standard for Severe Cases: For patients with severe obesity (BMI > 40) or those with comorbidities like type 2 diabetes, bariatric surgery continues to be an effective option despite its risks.
  • Comparative Efficacy of Non-Surgical and Surgical Interventions: The trial aims to clarify whether semaglutide and tirzepatide can provide comparable outcomes to bariatric surgery for weight loss and management of obesity-related diseases.
  • Advancements in Peptide Therapy Highlight New Treatment Avenues: As research into peptide-based treatments expands, the field offers new hope for patients seeking non-invasive alternatives to traditional surgical methods.

What This Means

For the peptide community, this study represents a significant step forward in understanding how newer medications can compete with established surgical options. If semaglutide and tirzepatide prove equally effective as bariatric surgery, it could shift treatment paradigms towards more accessible non-surgical interventions for obesity.

Moreover, this research underscores the growing importance of peptide therapy in treating complex health conditions like obesity. As these treatments continue to evolve, they may offer a safer alternative for many patients who might otherwise be unable or unwilling to undergo major surgical procedures.

---

Source: ClinicalTrials.gov — Published 2026-05-18

This article is for informational purposes only and does not constitute medical advice.

編集者の注

この分析はAIツールを使用して生成され、Peptide Contacts編集部がレビューしました。正確性を追求していますが、AI生成のコンテンツには誤りや省略がある可能性があります。情報確認のために常に元のソースをご確認ください。 元のソース 詳細、方法論、データについては

Peptide Contactsは、情報提供のために-curated研究要約を提供しています。このコンテンツは医療アドバイスにはなりません。健康決定をする前に常に格付けされた医療専門家に相談してください。

Comments

Sign in to join the discussion

この記事はAIを使用して生成され、誤りや省略がある可能性があります。情報提供のために提供されていますが、医療アドバイスにはなりません。常に元のソースを確認し、格付けされた医療専門家に相談してください。